Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 2/2010

01.04.2010 | Case Report

Gastric ulcer in a child treated with deferasirox

verfasst von: Tiene Bauters, Veerle Mondelaers, Hugo Robays, Kathleen Hunninck, Barbara de Moerloose

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

We present a patient with thalassemia major who developed a gastric ulcer, probably related to the use of deferasirox. Although gastric ulcer is mentioned as infrequent adverse event in the scientific product information of deferasirox, in our current knowledge, this is the first case-report on this adverse drug reaction. The severity of this event justifies the reporting of this case.
Literatur
2.
3.
Zurück zum Zitat Raphael JL, Bernhardt MB, Mahoney DH, Mueller BU. Oral iron chelation and the treatment of iron overload in a pediatric hematology center. Pediatr Blood Cancer. 2009;52(5):616–20.CrossRefPubMed Raphael JL, Bernhardt MB, Mahoney DH, Mueller BU. Oral iron chelation and the treatment of iron overload in a pediatric hematology center. Pediatr Blood Cancer. 2009;52(5):616–20.CrossRefPubMed
4.
Zurück zum Zitat Vanorden HE, Hagemann TM. Deferasirox. An oral agent for chronic iron overload. Ann Pharmacother. 2006;40(6):1110–7.CrossRefPubMed Vanorden HE, Hagemann TM. Deferasirox. An oral agent for chronic iron overload. Ann Pharmacother. 2006;40(6):1110–7.CrossRefPubMed
5.
Zurück zum Zitat Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455–62. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455–62.
6.
Zurück zum Zitat Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica. 2006;91(10):1343–51.PubMed Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica. 2006;91(10):1343–51.PubMed
10.
Zurück zum Zitat Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255–9.CrossRefPubMed Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255–9.CrossRefPubMed
Metadaten
Titel
Gastric ulcer in a child treated with deferasirox
verfasst von
Tiene Bauters
Veerle Mondelaers
Hugo Robays
Kathleen Hunninck
Barbara de Moerloose
Publikationsdatum
01.04.2010
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 2/2010
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-009-9357-1

Weitere Artikel der Ausgabe 2/2010

International Journal of Clinical Pharmacy 2/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.